Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...

West Pharmaceutical Services WST is scheduled to release fourth-quarter 2024 results on Feb. 13, before the opening bell. In ...

Adults with relapsing MS rated the Sensoready pen, an autoinjector used to self-administer Kesimpta, for ease of use and ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The inertial fusion energy project is funded by the U.S. Department of Energy (DOE) and includes the Lawrence Livermore ...